Abstract

BackgroundIn asthma management guidelines the primary goal of treatment is asthma control. To date, asthma control, guided by symptoms and lung function, is not optimal in many children and adults. Direct monitoring of airway inflammation in exhaled breath may improve asthma control and reduce the number of exacerbations.Aim1) To study the use of fractional exhaled nitric oxide (FeNO) and inflammatory markers in exhaled breath condensate (EBC), in the prediction of asthma exacerbations in a pediatric population. 2) To study the predictive power of these exhaled inflammatory markers combined with clinical parameters.Methods96 asthmatic children were included in this one-year prospective observational study, with clinical visits every 2 months. Between visits, daily symptom scores and lung function were recorded using a home monitor. During clinical visits, asthma control and FeNO were assessed. Furthermore, lung function measurements were performed and EBC was collected. Statistical analysis was performed using a test dataset and validation dataset for 1) conditionally specified models, receiver operating characteristic-curves (ROC-curves); 2) k-nearest neighbors algorithm.ResultsThree conditionally specified predictive models were constructed. Model 1 included inflammatory markers in EBC alone, model 2 included FeNO plus clinical characteristics and the ACQ score, and model 3 included all the predictors used in model 1 and 2. The area under the ROC-curves was estimated as 47%, 54% and 59% for models 1, 2 and 3 respectively. The k-nearest neighbors predictive algorithm, using the information of all the variables in model 3, produced correct predictions for 52% of the exacerbations in the validation dataset.ConclusionThe predictive power of FeNO and inflammatory markers in EBC for prediction of an asthma exacerbation was low, even when combined with clinical characteristics and symptoms. Qualitative improvement of the chemical analysis of EBC may lead to a better non-invasive prediction of asthma exacerbations.

Highlights

  • Asthma is the most common chronic inflammatory disorder in children [1]

  • Model 1 included inflammatory markers in exhaled breath condensate (EBC) alone, model 2 included fractional exhaled nitric oxide (FeNO) plus clinical characteristics and the Asthma Control Questionnaires (ACQ) score, and model 3 included all the predictors used in model 1 and 2

  • Qualitative improvement of the chemical analysis of EBC may lead to a better non-invasive prediction of asthma exacerbations

Read more

Summary

Introduction

Asthma is the most common chronic inflammatory disorder in children [1]. Worldwide epidemiological studies show that asthma is still not optimally controlled in many children and adults, despite proper pharmacotherapy and emphasis on asthma control in international asthma management guidelines [2,3,4,5,6]. Management of asthma and titration of treatment is based on the level of asthma control determined by symptoms and lung function [2,3,4]. These measures of asthma control do not give direct insight into the underlying inflammatory process. Measures of airway inflammation such as fractional exhaled nitric oxide (FeNO) and biomarkers in exhaled breath condensate (EBC) reflect airway inflammation in a non-invasive manner This is in contrast with an invasive procedure such as bronchoscopy with assessment of inflammatory markers in bronchial alveolar lavage or biopsies [8]. Direct monitoring of airway inflammation in exhaled breath may improve asthma control and reduce the number of exacerbations.

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call